^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)

i
Other names: Genetically modified HSPCs, Autologous CD34+ enriched HSPCs expressing interferon-alpha 2, TEM-GBM
Associations
Company:
Genenta Science
Drug class:
IFNα stimulant
Associations
1year
Impact on survival of interferon-alpha delivery in glioblastoma with unmethylated MGMT by immuno-gene therapy with Temferon (SNO 2023)
The other four patients with 2 year follow-up were treated with Gamma-Knife followed by bevacizumab (n = 1), regorafenib followed by bevacizumab (n = 1) and bevacizumab only (n = 2). These data corroborate the initial evidence on safety and tolerability of Temferon. They also suggest that Temferon has potential to counteract disease progression in patients affected by uMGMT GBM.
Gene therapy
|
IFNA1 (Interferon Alpha 1)
|
Avastin (bevacizumab) • Stivarga (regorafenib) • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
1year
MACROPHAGES-BASED IMMUNOTHERAPY OF SOLID TUMORS MICROENVIRONMENT: THE TEM-GBM STUDY (NCT03866109) (EANO 2023)
The comparison of the overall ISGs expression at first surgery and second surgery highlighted the activation of IFN-responsive genes at second surgery suggesting the occurrence of the local delivery within the TME of biologically active IFN-a. CONCLUSION The results provide initial evidence of Temferon’s potential to modulate the TME of GBM patients.
IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IRF7 (Interferon Regulatory Factor 7)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
1year
Genetic Engineering of Hematopoietic Progenitor Stem Cells for Targeted IFN-α Immunotherapy Reprogramming the Solid Tumor Microenvironment: A First-in-Man Study in Glioblastoma Multiforme (NCT03866109) (ASH 2023)
Autologous CD34+ HSPC are mobilized with lenograstim and plerixafor, collected by apheresis, purified and ex vivo modified with a lentiviral vector. So far, up to 3 million Temferon cells/kg have been co-administered with a fixed dose of non-manipulated CD34+ supporter cells following a sub-myeloablative conditioning regimen (Thiotepa + BCNU or Busulfan or Busulfan alone)... These data show that Temferon is safe and biologically active at the tumor site and favors anti-tumor immunity. The results provide initial evidence of Temferon's potential to modulate the TME of GBM patients and to counteract disease progression and improve the survival of uMGMT GBM patients.
IO biomarker
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IFNA1 (Interferon Alpha 1)
|
thiotepa • busulfan • Granocyte (lenograstim) • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) • plerixafor
almost2years
TEM-GBM: A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (clinicaltrials.gov)
P1/2, N=27, Recruiting, Genenta Science | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
2years
Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109) (ASH 2022)
Autologous CD34+ HSPC are mobilized with lenograstim and plerixafor, collected by apheresis, purified and ex vivo modified with a lentiviral vector that enables HSC TEMs progeny to be loaded with IFN-a. So far, up to 3 million Temferon cells/kg have been co-administered with a fixed dose of non-manipulated CD34+ supporter cells following a sub-myeloablative conditioning regimen (Thiotepa + BCNU/Busulfan)... Our interim results show that Temferon is well tolerated, with no dose limiting toxicities identified to date. The results provide initial evidence of Temferon's potential to modulate the TME of GBM patients, and anecdotal evidence for long lasting effects of Temferon in prevention of disease progression.
IO biomarker
|
CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IFNA1 (Interferon Alpha 1)
|
thiotepa • busulfan • Granocyte (lenograstim) • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) • plerixafor
2years
Modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109) (EANO 2022)
The results provide initial evidence of Temferon's potential to modulate the TME of GBM patients, and anecdotal evidence for long lasting effects of Temferon in prevention of disease progression.
Clinical
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • IFNA1 (Interferon Alpha 1)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
over2years
USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY) (EHA 2022)
Conclusion Our interim results show that Temferon is well tolerated, with no dose limiting toxicities identified to date. The results provide initial evidence of Temferon’s potential to modulate the TME of GBM patients.
IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IFNA1 (Interferon Alpha 1)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
over2years
Genetically modified Tie-2 expressing monocytes target IFN-α2 to the glioblastoma tumor microenvironment (TME): Preliminary data from the TEM-GBM Phase 1/2a study (AACR 2022)
TEM-GBM is an ongoing open-label, Phase 1/2a dose-escalating study evaluating the safety & efficacy of Temferon in up to 21 newly diagnosed patients with glioblastoma & unmethylated MGMT promoter assigned to 7 different cohorts (3 pts each) differing by Temferon dose (0.5-4.0x106/kg) and conditioning regimen (BCNU+ or Busulfan+Thiotepa). TCR sequencing of blood and tumor samples showed a post-treatment increase in the cumulative frequency of tumor-associated T cell clones identified in 1st and 2nd surgery specimens (up to 4 out of 9 subjects). These results provide initial evidence for on-target activity of Temferon in GBM, to be consolidated with longer follow up in the higher dose cohorts.
P1/2 data • IO biomarker
|
IFNA1 (Interferon Alpha 1)
|
thiotepa • busulfan • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
3years
TEM-GBM: A phase I-IIa dose-escalation study delivering IFN-α within glioblastoma multiforme tumor microenvironment by genetically modified Tie-2 expressing monocytes (SNO 2021)
TME characterization by scRNA and TCR sequencing is ongoing. Interim results show that Temferon is well tolerated, with no dose limiting toxicities identified to date and provide initial evidence of potential immune system activation within the TME.
P1/2 data
|
IFNA1 (Interferon Alpha 1)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
3years
TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN-α within Glioblastoma Tumor Microenvironment (ASH 2021)
Autologous CD34+ HSPC are mobilized with lenograstim and plerixafor, collected by apheresis, purified and transduced ex vivo with a 3 rd generation lentiviral vector encoding for IFN-a2...The study evaluates safety and biological activity of Temferon in 7 cohorts of three patients each, where escalating doses of Temferon are co-administered with a fixed CD34+ cell dose of non-manipulated supporter cells following a sub-myeloablative conditioning regimen (Thiotepa + BCNU or + Busulfan)... These interim results show that Temferon is generally well tolerated by patients, with no dose limiting toxicities identified to date. The results provide initial evidence of Temferon’s potential to activate the immune system and reprogram the tumor microenvironment (TME), as predicted by preclinical studies.
Clinical • P1/2 data • IO biomarker
|
IFNA1 (Interferon Alpha 1) • MIR126 (MicroRNA 126)
|
thiotepa • busulfan • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) • plerixafor
over3years
[VIRTUAL] Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study) (ASGCT 2021)
Tumor microenvironment characterization by scRNA & TCR sequencing is ongoing. The results support the safety of Temferon treatment & provide early evidence of its potential to modulate the TME of GBM patients as predicted by preclinical efficacy studies.
Clinical • IO biomarker
|
CD33 (CD33 Molecule)
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
over3years
[VIRTUAL] Inducible Tumor-Targeted Interferon-α Gene Therapy Inhibits Glioblastoma Multiforme in Mouse Model without Adverse Systemic Effects (ASGCT 2021)
The promising pre-clinical results obtained so far from our group led to the registration of the first drug based on this strategy, named Temferon®, which is currently in phase I/II clinical trial in our Institute for the treatment of patients with GBM. Our data also demonstrate the feasibility of inducible and intra-tumoral targeted delivery of an immune activating cytokine, thus opening the way to broader application to other cytokines and tumor types.
Preclinical
|
IFNA1 (Interferon Alpha 1)
|
IFNA1 expression
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
4years
[VIRTUAL] AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY) (SNO 2020)
Four SAEs occurred in 3 patients who received Temferon (pneumonia, pulmonary embolism, febrile neutropenia, fatigue) but these events were not attributed to Temferon, resolved, & may have been related to the conditioning regimen (carmustine & thiotepa). Disease progression has been confirmed in 3 patients who received Temferon. These preliminary results indicate feasibility of engrafting a pre-determined fraction of Temferon cells in the bone marrow of GBM patients without, so far, causing dose-limiting toxicity.
Clinical
|
CD34 (CD34 molecule) • CD14 (CD14 Molecule)
|
IFNG expression
|
carmustine • thiotepa • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
over4years
[VIRTUAL] AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-ALPHA2, RAPIDLY ENGRAFT AND MATURE IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY) (EHA 2020)
Autologous HSPCs are collected by single apheresis after G-CSF/Plerixafor stimulation & used to manufacture Temferon. Conditioning occurs with carmustine 400mg/m2 at D-6 & thiotepa 5mg/kg is given twice on D-5...Conclusion These preliminary results indicate feasibility of engrafting a pre-determined fraction of Temferon cells in the BM of GBM patients, which stabilizes after D+60 & remains detectable until the latest follow up. Updated results will be presented.
Clinical
|
CD8 (cluster of differentiation 8) • CD34 (CD34 molecule) • CD14 (CD14 Molecule)
|
IFNA1 expression
|
carmustine • thiotepa • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) • plerixafor
over4years
Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-Alpha2 (Temferon), Rapidly Engraft and Mature in Patients with Glioblastoma Multiforme (TEMGBM_001 Study) (ASGCT 2020)
Autologous HSPCs were collected by single apheresis after G-CSF/Plerixafor stimulation...Conditioning occurred with carmustine 400mg/m2 at D-6 & thiotepa 5mg/kg given twice on D-5...In summary, these preliminary results indicate feasibility of engrafting a pre-determined fraction of Temferon cells in the BM of GBM patients, which stabilizes after D+60 & remains detectable until the latest follow up. Updated results will be presented.
Clinical
|
CD8 (cluster of differentiation 8) • CD34 (CD34 molecule) • CD14 (CD14 Molecule)
|
IFNA1 expression
|
carmustine • thiotepa • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2) • plerixafor